TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02415699
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02415699
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03962725
Drug: Neuromuscular Blocking Agents
Normalized name: NEUROMUSCULAR BLOCKING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of non depolarizing neuromuscular blocking agents for maintenance of general anesthesia.
Study: NCT03962725
Drug: Anesthetic Adjuncts
Normalized name: ANESTHETIC ADJUNCTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine for maintenance of general anesthesia.
Study: NCT01565369
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection, 370MBq (10mCi), single dose
Study: NCT00591201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.
Study: NCT01691521
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
Study: NCT01691521
Drug: SC Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
Study: NCT00058201
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00793624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
Study: NCT00793624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for comparison Formoterolon safety and efficacy in COPD patients
Study: NCT00774527
Drug: Cyclophosphamide-fludarabine-anti thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~* Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).~* Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2.
Study: NCT03064854
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for solution for infusion
Study: NCT00058201
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02343003
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivery of corticosteroid into knee by injection with needle to reduce knee pain
Study: NCT00500721
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.~Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.~Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10.
Study: NCT02573831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
Study: NCT03756727
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in Ascorbic acid group received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery (once a day).
Study: NCT04015076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Match
Study: NCT03370575
Drug: the second-generation non-ionic monomer contrast
Normalized name: NON-IONIC CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysterosalpingography using the second-generation non-ionic monomer contrast
Study: NCT02693821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 300 mg per day, orally during 30 days
Study: NCT01939886
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03301597
Drug: Standard of Care (SOC) chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
Study: NCT00177281
Drug: S CKD602
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02712125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo vaginal tablets once daily until delivery
Study: NCT00466102
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy
Study: NCT00466102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets are taken once daily during study therapy
Study: NCT01632904
Drug: HU-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently.
Study: NCT01045083
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single dose
Study: NCT01045083
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single dose
Study: NCT04721704
Drug: Clarithromycin+ Amoxicillin + Omeprazole
Normalized name: AMOXICILLIN/OMEPRAZOLE/RIFABUTIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI will be given to children
Study: NCT04283292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream that is applied once topically
Study: NCT03582605
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: see previous descriptions
Study: NCT00427206
Drug: acetaminophen (4g/day)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00427206
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02059434
Drug: LAS190792 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02059434
Drug: LAS190792 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02059434
Drug: LAS190792 Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02059434
Drug: LAS190792 Dose 4
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02059434
Drug: LAS190792 Dose 5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02059434
Drug: LAS190792 Dose 6
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02059434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01190995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
Study: NCT04240158
Drug: IW-6463
Approvals — FDA: no, EMA: no, PMDA: no
Description: IW-6463 Tablet
Study: NCT04240158
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Tablet
Study: NCT00118742
Drug: mycophenolate mofetil [CellCept]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-1.5 g orally or intravenously twice daily
Study: NCT02634034
Drug: A: NK-104-CR 8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK-104-CR 8 mg (Controlled Release single 8-mg tablet)
Study: NCT01668524
Drug: ATS907
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of each of three increasing concentrations
Study: NCT03635905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose placebo capsule
Study: NCT03191136
Drug: YHD1119 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1:a single dose of YHD1119 300mg is administered in fasting condition Period 2:a single dose of YHD1119 300mg is administered in fed condition
Study: NCT03935152
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule
Study: NCT00564447
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin topical solution 1% given as a single drop in a single eye
Study: NCT00402532
Drug: Mycophenolatmofetil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dosage 2 x 500 mg/d intravenous
Study: NCT02487771
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of Soybean Oil and Corn Oil, which does not contain any DHA
Study: NCT00492882
Drug: usual administration of exogenous recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02307591
Drug: Best Supportive Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is \>7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
Study: NCT01949233
Drug: Doxycycline 100-200mg capsules daily for 6 months
Normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01949233
Drug: Doxycycline placebo capsules daily for 6 months
Normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03891472
Drug: Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX \> SBRT \> mFOLFIRINOX \> Surgical Intervention
Study: NCT01104246
Drug: Testerone Transdermal System
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone applied daily for 4 weeks
Study: NCT00483834
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m\^2 or 750mg/m\^2 for patients over 65yrs old PO BID, day 1-14 each cycle
Study: NCT01379976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal.
Study: NCT04446845
Drug: Double Stimulation (Elonva+rFSH) in luteal /follicular phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the 2nd oocyte retrieval, the patient will start luteal phase support (LPS) with vaginal micronized progesterone 200mg x 3 times a day until the day of the pregnancy test. All embryos will be cultured until day 5 in time-lapse incubators. In case of no blastocyst in the second cycle, or in case of poor embryo quality and in case of availability of frozen embryos from the first stimulation cycle, 1 frozen blastocyst from the first cycle will be thawed and will be transferred 5 days following the 2nd oocyte retrieval. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of ovarian hyperstimulation syndrome (OHSS) or progesterone elevation which is considered clinically relevant on the day of human chorionic gonadotropin (hCG) trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
Study: NCT04446845
Drug: Conventional Stimulation (Elonva+rFSH) in follicular phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: From the day of oocyte retrieval, the patients will be asked to start the LPS with vaginal micronized progesterone 3 times a day until the day of the pregnancy test. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of OHSS or progesterone elevation which is considered clinically relevant on the day of hCG trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
Study: NCT04612881
Drug: fitostimoline vaginal pessaries
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal pessaries
Study: NCT01226901
Drug: MK-4827
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-4287, 150 mg or 300 mg capsule, orally, once daily in 21 day cycles.
Study: NCT03515382
Drug: GLPG1690
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of GLPG1690.
Study: NCT00307632
Drug: Norelgestromine (NLGM)/ethinyl estradiol (EE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will apply a 20 centimeter square (cm\^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
Study: NCT00175032
Drug: Lansoprazole and naproxen and aspirin
Normalized name: naproxen and diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
Study: NCT00175032
Drug: Celecoxib and aspirin
Normalized name: amlodipine and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
Study: NCT03034018
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo taken at bedtime for four weeks
Study: NCT01905501
Drug: Balanced anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Et-Sevo maIntained 1,8-2%, remifentanyl according target-controlled infusion maintained 1-3 ng/ml
Study: NCT01905501
Drug: Total intravenous anesthesia
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3-4 µg/ml and remifentanyl 1-3 ng/ml according target-controlled infusion
Study: NCT01301781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI801 placebo - oral solution
Study: NCT00953537
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04738422
Drug: Alkaline glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will inhale alkaline glycine via nebulizer. Alkaline glycine is an alkaline medication designed for medication.
Study: NCT03889470
Drug: NTG 1 MG/ML Injectable Solution
Normalized name: NTG 1 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered after sheath placement
Study: NCT00432081
Drug: indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01036022
Drug: GSK1399686
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.
Study: NCT01902758
Drug: ambrisentan and theophylline
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01902758
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for comparison group
Study: NCT05642624
Drug: Deoxycholic acid amphotericin B
Normalized name: Deoxycholic Acid
DrugBank: Deoxycholic acid (DB03619)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.
Study: NCT01425970
Drug: Placebo matching with INX-08189
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, 0 mg, Once daily (QD), 12 weeks
Study: NCT03642860
Drug: Placebo Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment with Safflower oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
Study: NCT00612534
Drug: Sufentanil NanoTab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Study: NCT00612534
Drug: Sufentanil NanoTab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Study: NCT00612534
Drug: Sufentanil NanoTab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Study: NCT02378415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Infusion
Study: NCT01721915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00157911
Drug: Comparator: simvastatin / Duration of Treatment: 12 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03023111
Drug: Sbv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for CL, parenteral drug used during 20 days.
Study: NCT02243241
Drug: Placebo for HYD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match HYD tablets administered orally every 24 hours.
Study: NCT00511979
Drug: Regular human insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00250458
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose matching placebo to Rizatriptan to treat one migraine attack.
Study: NCT03613558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline solution
Study: NCT02026817
Drug: HCP1201 750/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
Study: NCT02026817
Drug: Rosuvastatin 10mg
Normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
Study: NCT01286441
Drug: 10% EISO
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the Treatment Period, subjects will apply study medication (10% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Study: NCT01286441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the Treatment Period, subjects will apply placebo to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Study: NCT01286441
Drug: 20% EISO
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the Treatment Period, subjects will apply study medication (20% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Study: NCT01103102
Drug: Iocide Oral Rinse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration
Study: NCT01103102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01286441
Drug: 30% EISO
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the Treatment Period, subjects will apply study medication (30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Study: NCT03017326
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arms C, D and E used in combination
Study: NCT00711828
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO